全文获取类型
收费全文 | 36266篇 |
免费 | 2212篇 |
国内免费 | 798篇 |
专业分类
耳鼻咽喉 | 142篇 |
儿科学 | 761篇 |
妇产科学 | 257篇 |
基础医学 | 4760篇 |
口腔科学 | 562篇 |
临床医学 | 2978篇 |
内科学 | 8706篇 |
皮肤病学 | 362篇 |
神经病学 | 2645篇 |
特种医学 | 710篇 |
外国民族医学 | 3篇 |
外科学 | 2386篇 |
综合类 | 5023篇 |
现状与发展 | 3篇 |
预防医学 | 2358篇 |
眼科学 | 208篇 |
药学 | 4290篇 |
16篇 | |
中国医学 | 1354篇 |
肿瘤学 | 1752篇 |
出版年
2023年 | 441篇 |
2022年 | 934篇 |
2021年 | 1292篇 |
2020年 | 1072篇 |
2019年 | 1117篇 |
2018年 | 1206篇 |
2017年 | 1033篇 |
2016年 | 1128篇 |
2015年 | 1230篇 |
2014年 | 2483篇 |
2013年 | 2673篇 |
2012年 | 2116篇 |
2011年 | 2477篇 |
2010年 | 1766篇 |
2009年 | 1864篇 |
2008年 | 1795篇 |
2007年 | 1640篇 |
2006年 | 1550篇 |
2005年 | 1363篇 |
2004年 | 1175篇 |
2003年 | 954篇 |
2002年 | 753篇 |
2001年 | 731篇 |
2000年 | 592篇 |
1999年 | 549篇 |
1998年 | 437篇 |
1997年 | 367篇 |
1996年 | 318篇 |
1995年 | 346篇 |
1994年 | 327篇 |
1993年 | 365篇 |
1992年 | 319篇 |
1991年 | 269篇 |
1990年 | 270篇 |
1989年 | 215篇 |
1988年 | 184篇 |
1987年 | 147篇 |
1986年 | 148篇 |
1985年 | 227篇 |
1984年 | 288篇 |
1983年 | 123篇 |
1982年 | 196篇 |
1981年 | 140篇 |
1980年 | 107篇 |
1979年 | 97篇 |
1978年 | 68篇 |
1976年 | 66篇 |
1975年 | 60篇 |
1974年 | 63篇 |
1973年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Autoimmune thyroid diseases (AITD) and Type 1 diabetes (T1D) frequently occur in the same individual pointing to a strong shared genetic susceptibility. Indeed, the co-occurrence of T1D and AITD in the same individual is classified as a variant of the autoimmune polyglandular syndrome type 3 (designated APS3v). Our aim was to identify new genes and mechanisms causing the co-occurrence of T1D + AITD (APS3v) in the same individual using a genome-wide approach. For our discovery set we analyzed 346 Caucasian APS3v patients and 727 gender and ethnicity matched healthy controls. Genotyping was performed using the Illumina Human660W-Quad.v1. The replication set included 185 APS3v patients and 340 controls. Association analyses were performed using the PLINK program, and pathway analyses were performed using the MAGENTA software. We identified multiple signals within the HLA region and conditioning studies suggested that a few of them contributed independently to the strong association of the HLA locus with APS3v. Outside the HLA region, variants in GPR103, a gene not suggested by previous studies of APS3v, T1D, or AITD, showed genome-wide significance (p < 5 × 10−8). In addition, a locus on 1p13 containing the PTPN22 gene showed genome-wide significant associations. Pathway analysis demonstrated that cell cycle, B-cell development, CD40, and CTLA-4 signaling were the major pathways contributing to the pathogenesis of APS3v. These findings suggest that complex mechanisms involving T-cell and B-cell pathways are involved in the strong genetic association between AITD and T1D. 相似文献
12.
13.
《Molecular therapy》2022,30(12):3587-3600
- Download : Download high-res image (165KB)
- Download : Download full-size image
14.
Ana M. Gómez Angelica Imitola Diana Henao Maira García-Jaramillo Marga Giménez Clara Viñals Bruno Grassi Mariana Torres Isabella Zuluaga Oscar Mauricio Muñoz Martin Rondón Fabián León-Vargas Ignacio Conget 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):267-272
Background and aimsDespite using sensor-augmented pump therapy (SAPT) with predictive low-glucose management (PLGM), hypoglycemia is still an issue in patients with type 1 Diabetes (T1D). Our aim was to determine factors associated with clinically significant hypoglycemia (<54 mg/dl) in persons with T1D treated with PLGM-SAPT.Methodology: This is a multicentric prospective real-life study performed in Colombia, Chile and Spain. Patients with T1D treated with PLGM-SAPT, using sensor ≥70% of time, were included. Data regarding pump and sensor use patterns and carbohydrate intake from 28 consecutive days were collected. A bivariate and multivariate Poisson regression analysis was carried out, to evaluate the association between the number of events of <54 mg/dl with the clinical variables and patterns of sensor and pump use.Results188 subjects were included (41 ± 13.8 years-old, 23 ± 12 years disease duration, A1c 7.2% ± 0.9). The median of events <54 mg/dl was four events/patient/month (IQR 1–10), 77% of these events occurred during day time. Multivariate analysis showed that the number of events of hypoglycemia were higher in patients with previous severe hypoglycemia (IRR1.38; 95% CI 1.19–1.61; p < 0.001), high glycemic variability defined as Coefficient of Variation (CV%) > 36% (IRR 2.09; 95%CI 1.79–2.45; p < 0.001) and hypoglycemia unawareness. A protector effect was identified for adequate sensor calibration (IRR 0.77; 95%CI 0.66–0.90; p:0.001), and the use of bolus wizard >60% (IRR 0.74; 95%CI 0.58–0.95; p:0.017).ConclusionIn spite of using advanced SAPT, clinically significant hypoglycemia is still a non-negligible risk. Only the identification and intervention of modifiable factors could help to prevent and reduce hypoglycemia in clinical practice. 相似文献
15.
目的 探讨血清谷丙转氨酶(ALT)与新诊2型糖尿病(T2DM)患病风险之间的关联,为T2DM的防治提供科学依据。方法 采用4阶段分层随机抽样的方法选取2006年和2009年参与青岛糖尿病预防项目的研究对象男性3 012例、女性4 422例,采用Pearson相关检验分析不同性别ALT与FPG、2 h PG的相关性,并利用多因素logistic回归分析ALT与新诊T2DM患病的关系。结果 男性中,ALT与空腹血浆血糖(FPG)、餐后2 h血浆血糖(2 h PG)的Pearson相关系数分别为0.088、0.080(均P<0.01);多因素logistic回归显示,在调整了年龄、BMI、糖尿病家族史、城乡、教育、婚姻、收入、吸烟及饮酒状况等混杂因素后,ALT的第4分位(Q4)组新诊T2DM患病风险是第1分位(Q1)组的1.832倍(OR = 1.832,95% CI:1.324~2.534,P<0.01)。女性中,ALT与FPG、2h PG的Pearson相关系数分别为0.065、0.108(均P<0.01);多因素logistic回归显示,在调整了年龄、BMI、糖尿病家族史、城乡、教育、婚姻、收入、吸烟及饮酒状况等混杂因素后,ALT的第4分位(Q4)组新诊T2DM患病风险是第1分位(Q1)组的1.445倍(OR = 1.445,95% CI:1.087~1.919,P<0.05)。结论 在男、女性人群中,ALT水平升高与T2DM患病相关,且这种相关性不受年龄、BMI、糖尿病家族史等的影响。 相似文献
16.
Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes. Therefore, it is necessary for cardiologists, patients with diabetes, and nephrologists to fully understand this type of drug. In this review, we summarize the following three aspects of SGLT2 inhibitors: the recent clinical evidence of their cardiovascular benefits, their mechanisms of action, and their safety. 相似文献
17.
18.
- Download : Download high-res image (66KB)
- Download : Download full-size image
19.
Roberto V.P. Ribeiro Mitesh V. Badiwala Danny Ramzy Laura C. Tumiati Vivek Rao 《The Journal of thoracic and cardiovascular surgery》2019,157(2):615-625.e1
Objective
Hypertonic saline (HTS) has potent immune and vascular effects. We assessed recipient pretreatment with HTS on allograft function in a porcine model of heart transplantation and hypothesized that HTS infusion would limit endothelial and left ventricular (LV) dysfunction following transplantation.Methods
Heart transplants were performed after 6 hours of cold ischemic storage. Recipient pigs were randomized to treatment with or without HTS (7.5% NaCl) before cardiopulmonary bypass (CPB). Using a myograft apparatus, coronary artery endothelial-dependent (Edep) and -independent (Eind) relaxation was assessed. LV performance was determined using pressure-volume loop analysis. Pulmonary interleukin (IL)-2, IL-6, and tumor necrosis factor (TNF)-α expression was measured.Results
Weaning from CPB and LV performance after transplantation were improved in HTS-treated animals. Successful weaning from CPB was greater in the HTS-treated hearts (8 of 8 vs 2 of 8; P < .05). Mean LV functional recovery was improved in the HTS-treated animals, as assessed by preload recruitable stroke work (65 ± 10% vs 27 ± 10%; P < .001) and end-systolic elastance (55 ± 7% vs 37 ± 4%; P < .001). Treatment with HTS resulted in improved Edep (mean maximum elastance [Emax], 56 ± 5% vs 37 ± 7%; P < .001) and Eind (mean Emax%, 77 ± 6% vs 52 ± 4%; P < .001) vasorelaxation compared with control. Pulmonary expression of IL-2, IL-6, and TNF-α increased following transplantation, whereas HTS therapy attenuated IL production (P < .001). Transplantation increased plasma TNF-α levels and LV TNF-α expression, whereas HTS prevented this up-regulation (P < .001).Conclusions
Recipient HTS pretreatment preserves allograft vasomotor and LV function, and HTS therapy limits CPB-induced injury. HTS may be a novel recipient intervention to prevent graft dysfunction. 相似文献20.